Hormones in Gynecologic Oncology: Treatment and Survivorship
Hormonal therapies have distinct roles in selected endometrial cancer settings and in survivorship symptom care. These are separate decisions, each requiring attention to tumor context and evidence limits.
Hormonal therapies have distinct roles in selected endometrial cancer settings and in survivorship symptom care. These are separate decisions, each requiring attention to tumor context and evidence limits.
Separate anticancer endocrine treatment from survivorship hormone care
“Hormones in gynecologic oncology” covers at least two different clinical questions. Endocrine treatment may be considered as part of cancer management in selected endometrial cancer settings. Hormone replacement therapy, by contrast, concerns symptoms and health after cancer treatment or risk-reducing surgery. The populations, goals, risks, and evidence bases differ. A discussion of one should not be used as a shortcut to a decision about the other.
The recent literature includes narrative reviews, evidence-based guidelines, and committee reviews. These sources help organize rapidly changing information, but they are not all primary comparative trials. Their value depends on the question being asked and on how closely an individual population matches the evidence summarized.
Endocrine treatment in endometrial cancer is selection-dependent
The 2025 review of endocrine treatment in endometrial cancer discusses fertility-preserving approaches for early-stage disease and options for advanced or recurrent disease. It describes progestin-based approaches, intrauterine levonorgestrel, and newer endocrine agents in hormone-sensitive settings, while noting recurrence risk and the role of biomarkers and molecular subtyping in patient selection.
This is a review of a diverse treatment area, not a single protocol. The phrase “selected patients” matters: the source does not support treating every endometrial cancer with endocrine therapy or using fertility-sparing treatment without careful eligibility assessment and follow-up. Response and recurrence are separate outcomes, and the suitability of a strategy depends on tumor and patient context.
Survivorship hormone therapy is individualized
The survivorship review addresses menopausal symptoms after gynecologic cancer and discusses hormone therapy in specific survivor groups. It emphasizes an individualized decision that considers cancer type and stage, symptom burden, timing, treatment goals, and patient preferences. It also describes nonhormonal approaches that may help manage symptoms, so the discussion need not be framed as a binary choice between systemic hormones and untreated symptoms.
The review’s language is not a blanket assurance for every cancer survivor. Its discussion refers to particular histologies and stages, and its recommendations must be interpreted within those boundaries. A source-level summary should preserve the subgroup context and avoid converting a review statement into a universal safety claim.
Guidelines provide a framework, not a substitute for source appraisal
The 2025 ESGO-ESTRO-ESP guideline update was developed after a systematic literature review and critical appraisal by an international multidisciplinary group, with patient representation and external review. It incorporates the updated FIGO staging framework and addresses diagnosis, management, follow-up, and patient education for endometrial carcinoma. The two-part Society of Gynecologic Oncology review also describes evidence grading and committee review.
Guidelines and committee reviews are useful for organizing decisions, but the certainty may differ from recommendation to recommendation. A summary should identify the guideline and version, distinguish evidence-supported recommendations from areas of uncertainty, and prompt clinicians to consult the full current document. It should not reproduce an abbreviated algorithm as if it were the complete guidance.
The year-in-review perspective is broad, not exhaustive
The 2025 gynecologic cancer year-in-review offers a high-level synthesis of developments across disease types. Such a review can help readers identify themes and navigate new publications, but it is not a systematic search designed to answer one narrowly framed treatment question. It should be used as a starting point for locating primary studies and current guidance, not as sole evidence for a specific intervention.
Likewise, Part I and Part II of the SGO evidence-based review are complementary publications, not duplicate copies. Their shared endometrial cancer scope and overlapping development process should be preserved in the catalog, while each part should be cited separately according to its content and identifier.
Evidence boundaries worth keeping visible
The source set includes secondary reviews and guideline documents rather than one unified prospective trial. Some treatment questions may rely on selected cohorts or evolving evidence, and evidence about anticancer endocrine therapy does not answer the safety question for survivorship hormone replacement. Similarly, evidence from one histology, stage, or symptom context should not be generalized to another without support.
The abstracts do not provide a single shared effect estimate across these sources. A concise evidence brief should avoid inventing pooled numbers, should not present a hormone regimen as a prescription, and should clearly distinguish literature review from direct clinical evidence. Where the full recommendation or evidence grading matters, clinicians should consult the cited primary article or guideline.
A structured conversation for the care team
For an endocrine treatment question, define the cancer setting, stage, histology, molecular context, treatment intent, and outcome of interest. For a survivorship hormone question, define the cancer history, symptom burden, treatment effects, alternatives, and relevant risks. Then identify which source actually addresses that group and whether it is a primary study, review, or guideline.
The literature supports individualized, evidence-aware discussion rather than a universal hormone rule. This overview is for professional education and does not replace the treating team’s review of the full record, patient preferences, or current locally applicable guidance.
PubMed sources
- State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.PubMed DOI
- Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers.PubMed DOI
- ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025.PubMed DOI
- Gynecologic cancers in 2025: a year in review.PubMed DOI
- Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I.PubMed DOI
- Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations, part II.PubMed DOI